{'fraction_non_alphanumeric': 0.026167471819645734, 'fraction_numerical': 0.002818035426731079, 'mean_word_length': 5.437823834196891, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Experimental Dermatology launches a new type of manuscript: ‘BEDSIDE‐TO‐BENCH LETTER’

Starting from August 2015, Experimental Dermatology will launch a new type of manuscript category, called ‘BEDSIDE-TO-BENCH LETTER’, which is designed to emphasize the importance of translational research in our field. This novel type of LETTER is intended to close a long-existing gap between classical case reports, hypothesis letters and viewpoints. To date, case reports are only considered in Experimental Dermatology if they contain a substantial experimental data component. Instead, ‘BEDSIDE-TO-BENCH LETTERS’ can now be used as a unique platform for bridging clinical and experimental dermatology by calling attention to intriguing and instructive clinical cases that shed light on disease pathobiology or novel skin biology aspects. The key characteristic for a case report manuscript to be eligible for publication in Experimental Dermatology as a ‘BEDSIDE-TOBENCH LETTER’ is that the authors can develop a clear-cut strategy for experimental research that emanates from the case they are reporting and that promises important advances in translational skin biology or skin pathology. For example, a clinician observing an unexpected improvement of a skin disease by a novel biologic or targeted treatment that was initiated to treat another disease of the patient, or who observes an interesting skin sign or symptom that raises fundamental questions on basic skin biology or pathology which can be addressed in a well-defined set of experiments, is strongly invited to transform this observation into a ‘BEDSIDE-TO-BENCH LETTER’. The structure of this innovative type of LETTER manuscript must include (i) a concise presentation of the case supported by key photographic documentation ideally together with histology or immunohistology (= bedside aspect), (ii) proposal of the obtained novel insight into disease pathogenesis, skin biology or new treatment strategy, and (iii) detailed outline of a translational research program (= bench). The maximum length of this ‘BEDSIDE-TO-BENCH LETTER’ is 800 words with one composite figure and nine references. Authors are encouraged to make use of an extensive e-supplement with additional text, figures, tables and references. Like all LETTERS in Experimental Dermatology, this new LETTER category will be freely accessible via PubMed without the need to have a subscription to the journal and thus enjoys unusually good public visibility.